Medarex, Inc. (NASDAQ: MEDX) wants to clarify a few issues regarding the study halt from Pfizer (NYSE: PFE) this week on advanced melanoma. The company says that there are key differences between…
Medarex Inc. (NASDAQ: MEDX) Saw shares plummet in pre-market trading. Pfizer Inc. (NYSE: PFE) has ended a Phase III clinical trial of tremelimumab in patients with advanced melanoma after a review of…
Those rummaging through the garbage of 52-week low lists are usually bottom-fishing investors or desperate CEOs. But, the list is so broad that it has become a tableau of the market as…
This was a massive list of lows today. Not all closed on lows, but the list was chopped down greatly just to accommodate the size of it. If you look at the…
CyDex Pharmaceuticals, Inc. has filed to come public via an IPO in what it lists for filing purposes as up to $50 million in securities sales. It has applied to have the…
Pfizer Inc. (NYSE: PFE) has given some of its basic data points for its analyst meeting today. For starters, the company has reaffirmed its guidance for 2008 that it previously offered. That…
Douglas A. McIntyre These are not the only analyst calls affecting shares of stock this morning, but these are the initial calls that 247WallSt.com is focusing on: AIG (NYSE: AIG) cut to Market Perform at…
Antigenics Inc. (NASDAQ: AGEN) A study for Cancer vaccine, Oncophage, for the treatment of metastatic melanoma showed mixed results this morning. Shares are down almost 7% to $2.17. The 52 week range…
Douglas A. McIntyre Icagen Inc. (NASDAQ: ICGN) has announced that it has provided notice to exercise its put option with Pfizer Inc. (NYE: PFE). This is for the private placement of approximately $10 million of…
Douglas A. McIntyre 2008 is turning out to be a wacky year. If you are new to trading and investing this is far from the norm. Statistics vary depending on what day of the week…
Pfizer Inc. (NYSE: PFE) has posted earnings that are lower than last year’s results, but were actually above analyst expectations from First Call. The drug giant posted $0.52 EPS versus $0.47 estimates…
Douglas A. McIntyre Monday is a market holiday in observance of Martin Luther King Day in the U.S. But after that we have an earnings deluge with hundreds of companies issuing their earnings. For the…
Short interest of stocks listed on the NYSE as of December 31 showed that retailers and financial companies had sharp increases when compared to the figures on December 14. Shares sold short…
We are updating our list of tier-one Defensive Stocks since so many of these stocks have run up and since lists need continual updating. Our originally updated list of tier one defensive…
We compiled a list of many companies that just haven’t been able to turn themselves around. On some we offered a road out and on others we feel sorry for the management…
Douglas A. McIntyre